{"id":"W2947494310","doi":"10.1200/jco.2019.37.15_suppl.3094","title":"A first-in-human phase I/II trial of SRA737 (a Chk1 Inhibitor) in subjects with advanced cancer.","year":2019,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Cancer Genomics and Diagnostics","field":"Biochemistry, Genetics and Molecular Biology","cited_by":31,"is_retracted":false,"has_abstract":true,"ca_institutions":"Sierra Wireless (Canada)","funders":"","keywords":"Medicine; Tolerability; Toxicity; Pharmacokinetics; Dosing; Internal medicine; Prostate cancer; Adverse effect; Phases of clinical research; Gastroenterology; Urology; Cancer","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001741678,0.002090993,0.001789977,0.0004605295,0.0006918813,0.0007508057,0.0008244032,0.001199355,0.006178415],"category_scores_gemma":[0.0006347459,0.0006125467,0.0008470713,0.0003960859,0.0009664154,0.0007577264,0.0004459135,0.003031193,0.001757857],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.000933581,"about_ca_system_score_gemma":0.002112981,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.001296907,"about_ca_topic_score_gemma":0.004013048,"domain_scores_codex":[0.9995345,0.000197961,0.00001590135,0.00008431456,0.00003436188,0.0001330973],"domain_scores_gemma":[0.9994098,0.00008177506,0.00007219459,0.00004736209,0.0000423477,0.0003465764],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.7166178,0.1085722,0.005959949,0.0006850853,0.0007163563,0.0004561274,0.0003340697,0.001857539,0.06554516,0.0003379729,0.01095002,0.0879676],"study_design_scores_gemma":[0.4732333,0.5087019,0.008763018,0.00002249648,0.0002945338,0.0002685408,0.00004774438,0.0009457595,0.00347061,0.0002493409,0.003975702,0.0000270321],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.985302,0.001699541,0.000759984,0.0006252626,0.0001718893,0.005823108,0.00262377,0.0002166818,0.002777854],"genre_scores_gemma":[0.9803613,0.001171846,0.002414137,0.00131991,0.0002077575,0.00472576,0.004201749,0.0000554285,0.005542064],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.006178415,"threshold_uncertainty_score":0.02066886,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.03546129956307053,"score_gpt":0.4211166670666374,"score_spread":0.3856553675035669,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}